Soligenix, Inc. (LON:0A6I)
3.270
+0.509 (18.44%)
At close: Aug 6, 2025
Soligenix Revenue
Soligenix had revenue of $2.34K USD in the twelve months ending March 31, 2025, down -99.67% year-over-year. In the year 2024, Soligenix had annual revenue of $119.37K, down -85.78%.
Revenue (ttm)
$2.34K
Revenue Growth
-99.67%
P/S Ratio
3,410.54
Revenue / Employee
$146.38
Employees
16
Market Cap
6.18M GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 119.37K | -719.99K | -85.78% |
Dec 31, 2023 | 839.36K | -109.55K | -11.55% |
Dec 31, 2022 | 948.91K | 124.64K | 15.12% |
Dec 31, 2021 | 824.27K | -1.54M | -65.07% |
Dec 31, 2020 | 2.36M | -2.27M | -49.04% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AstraZeneca | 41.24B |
HSBC Holdings | 41.03B |
Shell | 198.54B |
Unilever | 51.24B |
British American Tobacco p.l.c. | 25.60B |
Rolls-Royce Holdings | 19.54B |
Rio Tinto Group | 39.22B |
BP p.l.c. | 134.89B |
Soligenix News
- 5 days ago - NetworkNewsAudio Announces Audio Press Release (APR) on Promising First-Line Therapy for Rare Skin Cancer - GlobeNewsWire
- 13 days ago - Crude Oil Falls 1%; Meta Earnings Top Views - Benzinga
- 13 days ago - Nasdaq Surges Over 1%; Microsoft Posts Upbeat Earnings - Benzinga
- 13 days ago - Biological Efficacy Demonstrated in a Phase 2 Clinical Trial of SGX945 for the treatment of Behçet's Disease - Benzinga
- 13 days ago - Biological Efficacy Demonstrated in a Phase 2 Clinical Trial of SGX945 for the treatment of Behçet's Disease - PRNewsWire
- 5 weeks ago - Soligenix Corporate Update Letter - Key Highlights and Upcoming Milestones - PRNewsWire
- 6 weeks ago - Soligenix Announces Synthetic Hypericin Successfully Manufactured at Sterling Pharma Solutions - PRNewsWire
- 2 months ago - Soligenix Highlights Dr. Ellen Kim's Recent Q&A and the Promise of HyBryte™ in Ongoing Clinical Trials - GlobeNewsWire